ANCA Vasculitis - Pipeline Insight, 2025

This “ANCA Vasculitis - Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

ANCA Vasculitis: Understanding

ANCA Vasculitis: Overview

Antineutrophilic cytoplasmic antibody (ANCA) associated Vasculitis are a heterogeneous group of rare autoimmune conditions that causes an inflammation of blood vessels with various manifestations. It includes three main diseases, which are granulomatosis with polyangiitis (GPA; formerly known as Wegener granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome), and microscopic polyangiitis (MPA). Other ANCA-associated diseases are drug-induced vasculitis and renal limited vasculitis.

Signs and symptoms of ANCA vasculitis include fatigue, fever, weight loss, and muscle or joint pain. It can cause specific organ involvement, leading to respiratory issues like cough or shortness of breath and kidney problems such as blood in the urine. Skin manifestations, including rashes or ulcers, may also occur. Additionally, patients may experience nerve damage, resulting in numbness or weakness, and gastrointestinal symptoms like abdominal pain or diarrhea.

It is still unknown how the antineutrophilic cytoplasmic antibody (ANCA) antibodies develop. Some studies suggest a genetic role. In two studies, there was an association between the anti-PR3-ANCA and HLA-DP, PRTN3 (the gene encoding proteinase-3), and anti-MPO ANCA was associated mainly with HLA-DQ polymorphisms. Some studies link the development of ANCA antibodies to environmental causes or infections, proposing the molecular mimicry model. In vitro studies showed that neutrophils are initially primed (partially stimulated) with TNF-alpha, lipopolysaccharide (LPS), or complement (C5a), then it will be activated once it is bound to the ANCA. After activation, it will degranulate and mediate endothelial cell damage. The diagnosis of vasculitis needs a high index of suspicion because of the rarity of the disease and the multisystemic nature of vasculitis. A detailed history and physical examination are key in the management of vasculitis. A complete workup is required to establish the diagnosis, rule out other causes, and evaluate the severity of the disease and organ involvement. To establish the diagnosis, a combination of clinical assessment with serological testing is needed, and a tissue biopsy many times confirms the diagnosis.  

'ANCA Vasculitis- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ANCA Vasculitis pipeline landscape is provided which includes the disease overview and ANCA Vasculitis treatment guidelines. The assessment part of the report embraces, in depth ANCA Vasculitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ANCA Vasculitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence ANCA Vasculitis R&D. The therapies under development are focused on novel approaches to treat/improve ANCA Vasculitis.

ANCA Vasculitis Emerging Drugs Chapters

This segment of the ANCA Vasculitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

ANCA Vasculitis Emerging Drugs

Abatacept: Bristol-Myers Squibb

Abatacept is a selective T-cell co-stimulation modulator. Abatacept binds to CD80 and CD86 receptors on antigen-presenting cells (APCs), which are essential for T-cell activation. This binding blocks the interaction between CD80/CD86 and CD28, thereby inhibiting the delivery of the second co-stimulatory signal required for optimal T-cell activation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ANCA Vasculitis.

Sparsentan : Travere Therapeutics

Sparsentan is a dual endothelin and angiotensin II receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Sparsentan acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), which are involved in the pathogenesis of IgAN. It selectively blocks the action of endothelin-1 (ET-1) and angiotensin II (Ang II) at their respective receptors, thereby reducing proteinuria. The drug is currently in Phase II of clinical trial evaluation for the treatment of ANCA Associated Vasculitis.

ANCA Vasculitis: Therapeutic Assessment

This segment of the report provides insights about the different ANCA Vasculitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in ANCA Vasculitis

• There are approx. 12+ key companies which are developing the therapies for ANCA Vasculitis. The companies which have their ANCA Vasculitis drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.

Phases

The report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

ANCA Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

ANCA Vasculitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ANCA Vasculitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ANCA Vasculitis drugs.

ANCA Vasculitis Report Insights

• ANCA Vasculitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

ANCA Vasculitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing ANCA Vasculitis drugs?
• How many ANCA Vasculitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ANCA Vasculitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the ANCA Vasculitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for ANCA Vasculitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bristol-Myers Squibb
• Travere Therapeutics
• Novartis Pharmaceuticals
• NS Pharma
• Staidson Biopharmaceuticals Co., Ltd

Key Products

• Abatacept
• Sparsentan
• Iptacopan
• NS-229
• STSA-1002

This product will be delivered within 2 business days.